Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can Brain-Triggered stimulation reawaken arms after stroke?

NCT ID NCT07098572

Symptom relief Sponsor: MED-EL Elektromedizinische Geräte GesmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This study tests whether a smarter electrical stimulation device can help people recover arm and hand movement after a stroke. Participants with moderate arm weakness will be randomly assigned to receive either standard cyclic stimulation or a new EMG-triggered stimulation that responds to their own muscle signals. Both groups will undergo treatment five times a week for three weeks, with follow-up assessments to measure changes in arm function and daily living skills.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Electromyogram-triggered four-channel neuromuscular stimulation (EMG-MES) compared to cyclic single-channel neuromuscular stimulation
What this could lead to
If effective, this approach could offer a more targeted rehabilitation method to improve arm and hand function after stroke, potentially enhancing independence and quality of life.
What could go wrong
This is a small, early-stage trial, and results may not apply to all stroke patients. The benefit over standard stimulation is uncertain, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 44 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * First-time ischemic stroke with moderate arm paresis (Motricity Index - UE Sum-Score ≥ 40 ≤ 77 points) (Collin \& Wade, 1990) * Early to late subacute phase (7 days - 6 months) (Bernhardt et al., 2017) * Existing ADL ability before the event (ICF d5 self-care, d6 domestic life, extent of problem ≤1 points) (WHO, 2001) * Age ≥18 - 99 years * Signed and dated ICF before the start of any study-specific procedure. Exclusion Criteria: * Lack of compliance with any inclusion criteria * Implanted defibrillators, brain stimulators, pacemakers, medication pumps * Therapy-resistant epilepsy * Fever or infectious diseases * Inflammatory or tumorous skin diseases in the stimulation area, * Thromboses or vein inflammations * Severe contractures of the affected extremity * Wounds in the stimulation area * Pregnancy * Known allergic reactions to components of the investigational medical device * Unstable psychological status * Participation in other pharmacological clinical investigations within four weeks prior to enrolment * Anything that, in the opinion of the Investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke Paresis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic stroke Moderate arm paresis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    3 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • KABEG Gailtal-Klinik LKH Hermagor

    RECRUITING

    Hermagor, Carinthia, 9620, Austria

  • Kepler Universitätsklinikum Linz

    RECRUITING

    Linz, Upper Austria, 4021, Austria

  • Ö. Landeskrankenhaus Hochzirl - Natters, Standort Hochzirl

    RECRUITING

    Zirl, Tyrol, 6170, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.